CD4+ T-cell recovery after allogeneic stem cell transplantation for acute myeloid leukemia
Main Article Content
Abstract
CD4+ T lymphocytes play a key role in immune regulation and protection against infection after allogeneic hematopoietic stem cell transplantation. This retrospective study included 78 patients with acute myeloid leukemia who underwent allogeneic peripheral blood stem cell transplantation at the National Institute of Hematology and Blood Transfusion. The study aimed to describe early CD4+ T-cell recovery and to identify factors associated with CD4+ reconstitution within the first 100 days after transplantation. The proportion of patients achieving CD4+ T-cell recovery, defined as a CD4+ T-cell count ≥ 200 cells/µL within 100 days after transplantation, was 65.4%. The cumulative probability of CD4+ T-cell recovery increased over time. In multivariable analysis, donor type remained independently associated with early CD4+ T-cell recovery. Patients receiving haploidentical transplantation had a lower likelihood of CD4+ recovery than those receiving fully matched transplantation (HR = 0.28; p < 0.001).
Article Details
Keywords
Allogeneic stem cell transplantation, T CD4 , immune reconstitution, acute myeloid leukemia
References
2. Nguyễn Hữu Chiến. Đánh giá kết quả điều trị Lơ xê mi cấp dòng tuỷ bằng ghép tế bào gốc tạo máu đồng loài giai đoạn 2012-2015. Luận án tiến sĩ y học, Trường Đại học Y Hà Nội. 2017.
3. Hammoudi T, Nucera S, Troullioud AG, et al. Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group. Blood Adv. 2025; 9(23): 6141-6157.
4. Kim DH, Sohn SK, Won DI, et al. Rapid helper T-cell recovery above 200 × 106/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. Bone Marrow Transplant. 2006; 37(12): 1119-1128.
5. Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016; 71(9): 2397-2404.
6. Ogonek J, Juric MK, Ghimire S, et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016; 7(NOV): 1-15.
7. EBMT Registry. Guide to the Completion of the EBMT Data Collection Form: HCT_FU_D100_v1.0. HCT Day 100 Follow-up. European Society for Blood and Marrow Transplantation; 2023.
8. Farina M, Chiarini M, Terlizzi S, et al. Immune Reconstitution after Allogenic Stem Cell Transplantation in Patients with Myelofibrosis. Blood. 2024; 144(1).
9. Holler E, Greinix H, Zeiser R. Acute graft-versus-host disease. In: Carreras E, Dufour C, Mohty M, Kröger N, eds. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. Springer; 2019: 323-330.
10. Oxford University Hospitals NHS Foundation Trust. Management of Cytomegalovirus (CMV) Reactivation and Infection in Allogeneic Blood and Marrow Transplant (BMT) Recipients. Version 6.0. Oxford University Hospitals NHS Foundation Trust; September 2024.
11. Heining C, Spyridonidis A, Bernhardt E, et al. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: A retrospective study including 148 patients. Bone Marrow Transplant. 2007; 39(10): 613-622.
12. Khimani F, Ranspach P, Elmariah H, et al. Increased infections and delayed CD4+ T-cell but faster B-cell Immune Reconstitution after Posttransplant Cyclophosphamide Compared to Conventional GVHD prophylaxis in Allogeneic Transplantation. Transplant Cell Ther. Published online 2021.
13. Meyer T, Maas-bauer K, Wäsch R, et al. Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide , ATLG and non-ATLG based GvHD prophylaxis. Bone Marrow Transplant. 2024; (November).
14. Kerbauy MN, Rocha FA, et al. Immune reconstitution dynamics after unrelated allogeneic transplantation with post-transplant cyclophosphamide compared to classical immunosuppression with anti-thymocyte globulin: a prospective cohort study. Haematologica. 2025; 110(3): 640-650.
15. Nunes NS, Kanakry CG. Mechanisms of Graft-versus-Host Disease Prevention by Cyclophosphamide: An Evolving Understanding. 2019; 10(November).